ஜேம்ஸ் பார்டர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from ஜேம்ஸ் பார்டர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In ஜேம்ஸ் பார்டர் Today - Breaking & Trending Today
Futura Medical PLC says the countdown to regulatory sign-off of erectile dysfunction gel has begun proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
TRADING UPDATES: Pelatro gets contracts; Futura raises GBP10 million Mon, 17th May 2021 15:04 (Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Pelatro PLC - London-based marketing software specialist - Secures several contracts for change requests, worth around USD300,000, that will be delivered in 2021. With these, the total value of contracts in hand representing 2021 revenue is around USD6.8 million. Comes around a month after firm reports getting several contracts for change requests, adding up to USD500,000, that brought total value of work in hand for 2021 revenue to USD6.5 million. Given that we have clear visibility with contracts secured for USD6.8 million of revenue for 2021 so early in the year, together with the momentum we are building in our business, we are looking forward to a successful outcome this year in line with expectations, says Chief Executive ....
Futura Medical’s CEO discusses £12m fundraising for MED3000 Futura Medical PLC s (LON:FUM) James Barder talks to Proactive London s Katie Pilbeam to explain the plans for their £12mln fundraise. Firstly, manufacturing scale up, the firm needs to commit to certain capex to fully automate production. They have also retained corporate advisers and are expecting to announce further distribution agreements during the remainder of 2021 in addition to the Asia agreement they announced in early March. Also following the clear guidance from the FDA regarding the protocol they have been able to accurately cost the study at £3 million. And finally to strengthen balance sheet and fund all required activities for the company through until at least US MED3000 launch. ....